The Ballydine site exports to more than 30 countries, including Japan, the US and much of Europe. It produces active pharmaceutical ingredients (APIs) for use by MSD subsidiaries throughout the world, including late stage clinical APIs.
The site includes a formulation, R&D and manufacturing facility, which supports MSD's initiative to bring new medicines to market more effectively. It develops innovative ways to formulate new products from pilot to commercial scale, and supplies tablets for late stage clinical trials, launch and early stage supply.
See career opportunities at Ballydine
Find us on Google Maps